title: Survival is not the only valuable end point in melanoma screening.
authors.affiliation: Division of Dermatology, Department of Medicine, University of Arizona, Tucson, Arizona, USA.
authors.forename: Clara
authors.initials: C
authors.lastname: Curiel-Lewandrowski
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Kim
authors.forename: Susan M
authors.initials: SM
authors.lastname: Swetter
authors.forename: Suephy C
authors.initials: SC
authors.lastname: Chen
authors.forename: Allan C
authors.initials: AC
authors.lastname: Halpern
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
authors.forename: Sancy A
authors.initials: SA
authors.lastname: Leachman
authors.forename: Ashfaq A
authors.initials: AA
authors.lastname: Marghoob
authors.forename: Michael E
authors.initials: ME
authors.lastname: Ming
authors.forename: James M
authors.initials: JM
authors.lastname: Grichnik
mesh_terms: D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer / Q000191:economics; D005189:False Positive Reactions; D006266:Health Education; D006801:Humans; D008545:Melanoma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D011322:Primary Prevention; D055502:Secondary Prevention; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology